Sarcopenia

Hiroyuki Asama(Fukushima Medical University), Shin Maeda(University of Tokyo Hospital), Satoshi Tanaka(Osaka Prefectural Medical Center), Satoshi Kobayashi(Kanagawa Cancer Center), Hiromasa Ohira(Fukushima Medical University), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Shuhei Nagashima(Kanagawa Prefectural Hospital Organization), Kuniyuki Kawano(Kanagawa Prefectural Hospital Organization), Taito Fukushima(Kanagawa Prefectural Hospital Organization), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Y. Sano(Shiga University of Medical Science)
Pancreas
February 1, 2022
10.1097/mpa.0000000000001985
Cited by 24

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|Annals of Oncology|2019|333
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
|˜The œLancet. Gastroenterology & hepatology|2019|331
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
|Japanese Journal of Clinical Oncology|2017|274